TREATMENT OF ARTHRITIS WITH ANTISENSE ORIGONUCLEOTIDE FOR TRANSCRIPTION FACTOR NF-κB
用转录因子 NF-κB 反义原核苷酸治疗关节炎
基本信息
- 批准号:11671446
- 负责人:
- 金额:$ 2.24万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:1999
- 资助国家:日本
- 起止时间:1999 至 2000
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
1. DBA/1J male mice were immunized with bovine type II collagen emulsified with Freund's incomplete adjuvant as a model for rheumatoid arthritis. Five mice were sacrificed at 3,5,7 weeks after the immunization. Knee joints were fixed in 10% neutralized formic acid, decalcified with 0.5% EDTA and embedded in paraffin. Histological changes were evaluated in sections stained with hematoxylin-eosin and immunostaining with rabbit anti-NF-κB p65 polyclonal antibodies (Santa Cruz) using avidin-biotin complex method. NF-κB was positive in synovial lining cells and chondrocytes. The mean rates of NF-κB-positive chondrocye at 3,5 and 7 weeks after the immunization were 43.7%, 68.0% and 79.5%. The rate of mice without treatment was 51.1%.2. Antisense oligonucleotide for NF-κB designed as 5'-GAA ACAGATCGTCCATGGT or a mismatched sense designed as 5'-GAAACAGATCGTCTATGGT was intraperitonealy injected into the DBA/1J mice 4 weeks after the immunization with type II collagen for 2 weeks every day. Significant inhibition of swelling and redness of pows was not observed. These findings indicated two critical problems as follows. One was a delivery system of the oligonucleotide, and the other was an effect of another transcription factor AP-1. After then we observed AP-1 expression in the lining cells of mouse air-pouch model induced by lipopolysaccharide. Further investigation on these points will be required.
1.弗氏不完全佐剂乳化牛II型胶原蛋白免疫DBA/1J雄性小鼠,作为类风湿性关节炎模型。免疫后3、5、7周处死5只小鼠。将膝关节固定在10%中和的甲酸中,用0.5%EDTA脱钙并包埋在石蜡中。使用抗生物素蛋白-生物素复合物方法,用苏木精-伊红染色和用兔抗NF-κB p65多克隆抗体(Santa Cruz)免疫染色的切片评估组织学变化。滑膜衬里细胞和软骨细胞中 NF-κB 呈阳性。免疫后3、5、7周NF-κB软骨细胞阳性率平均分别为43.7%、68.0%和79.5%。小鼠未治疗率为51.1%。2。在II型胶原免疫后4周,每天将设计为5'-GAA ACAGATCGTCCATGGT的NF-κB反义寡核苷酸设计为5'-GAA ACAGATCGTCCATGGT或设计为5'-GAAACAGATCGTCTATGGT的错配正义寡核苷酸设计为DBA/1J小鼠腹膜内注射,连续2周。没有观察到对战俘肿胀和发红的显着抑制。这些发现表明了以下两个关键问题。一个是寡核苷酸的递送系统,另一个是另一种转录因子AP-1的作用。然后我们观察脂多糖诱导的小鼠气囊模型内衬细胞中AP-1的表达。需要对这些点进行进一步调查。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Takagi T, Koshino T, Hayashi T, Sakurai S, Eguchi J: "Roles of NF-κB in destruction of articular cartilage. (in Japanese)."THE BONE. 14. 73-75 (2000)
Takagi T、Koshino T、Hayashi T、Sakurai S、Eguchi J:“NF-κB 在关节软骨破坏中的作用。(日语)。”THE BONE。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
桜井真一: "Lipopolysaccharide反復投与によるマウスair-pouch表層細胞のapoptosisと浸出液中soluble Fasの出現"日本整形外科学会誌. 73. S1645 (1999)
Shinichi Sakurai:“由于重复施用脂多糖,导致小鼠气囊表面细胞凋亡和渗出液中出现可溶性 Fas”,日本骨科学会杂志 73. S1645 (1999)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Sakurai S, Takagi T, Okamoto R, Hayashi T, Matsukura Y, Sato MI, Sato M, Kurosaka N, Eguchi J, Ogura K, Koshino T: "Apoptosis of the lining cells and up-regulation of soluble Fas in the exudates of the mouse air pouch induced by lipopolysaccharide. (in Ja
Sakurai S、Takagi T、Okamoto R、Hayashi T、Matsukura Y、Sato MI、Sato M、Kurosaka N、Eguchi J、Ogura K、Koshino T:“衬里细胞的凋亡和渗出物中可溶性 Fas 的上调
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
高木敏貴: "関節軟骨破壊とNF-κB"THE BONE. 14・3. 73-75 (2000)
高木俊树:“关节软骨破坏和 NF-κB”THE BONE 73-75 (2000)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
高木敏貴: "関節軟骨破壊とNF-κB"THE BONE. 14. 73-75 (2000)
Toshiki Takagi:“关节软骨破坏和 NF-κB”THE BONE 14. 73-75 (2000)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TAKAGI Toshitaka其他文献
TAKAGI Toshitaka的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TAKAGI Toshitaka', 18)}}的其他基金
ROLES OF ADHESION MOLECULE CD44 ON RHEUMATOID CHONDROCYTES IN ARTHRITIS
粘附分子 CD44 对关节炎中类风湿软骨细胞的作用
- 批准号:
08671673 - 财政年份:1996
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
SynaptixBio: Development of antisense oligonucleotide therapeutics for the treatment of rare paediatric TUBB4A-related leukodystrophies
SynaptixBio:开发反义寡核苷酸疗法,用于治疗罕见的儿科 TUBB4A 相关脑白质营养不良
- 批准号:
10067962 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Collaborative R&D
Development of antisense oligonucleotide therapy for Schaaf-Yang syndrome humanized model mouse
Schaaf-Yang综合征人源化模型小鼠反义寡核苷酸疗法的开发
- 批准号:
23K14957 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an UNC13A antisense oligonucleotide treatment for ALS and FTD
开发治疗 ALS 和 FTD 的 UNC13A 反义寡核苷酸
- 批准号:
10699613 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD
开发治疗 ALS 和 FTD 的 SYF2 反义寡核苷酸
- 批准号:
10547625 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent
分子刷偶联反义寡核苷酸作为泛 KRAS 耗竭剂
- 批准号:
10771051 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent
分子刷偶联反义寡核苷酸作为泛 KRAS 耗竭剂
- 批准号:
10544115 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Commercializing a novel platform for delivery of antisense oligonucleotide-mediated therapy
将用于反义寡核苷酸介导的治疗的新平台商业化
- 批准号:
462420 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Operating Grants
Research on personalized medicine using miR-4516 and antisense oligonucleotide for treating refractory neuroendocrine cancer
miR-4516和反义寡核苷酸治疗难治性神经内分泌癌的个体化医疗研究
- 批准号:
22K07230 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency
发现立体阻断反义寡核苷酸 (ASO) 以选择性纠正 NF1 单倍体不足
- 批准号:
10546542 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency
发现立体阻断反义寡核苷酸 (ASO) 以选择性纠正 NF1 单倍体不足
- 批准号:
10844204 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别: